Using UK electronic health records, researchers analyzed 3,579 IPF patients, matched with COPD patients for comparison
Drucker, who is an endocrinologist, Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology and professor of medicine in the division of endocrinology at University of Toronto and has a laboratory based in the Lunenfeld Tanenbaum Research Institute at Mount Sinai Hospital in Toronto, said GLP-1s have gone from scientists questioning why anyone would want to use an injectable sulfonylurea to a class of drugs that have numerous benefits, including: reductions in albuminuria, atherosclerosis, body weight, blood pressure, cell death, fibrosis, glucose, gut motility, inflammation, oxidative stress, platelet aggregation, postprandial lipemia and thrombosis
GLP-1 medications tested as well About half of the patients studied took newer GLP-1 drugs like semaglutide, sold as Ozempic and Wegovy, as well as tirzepatide, which is sold as Mounjaro and Zepbound
That being said, its important to be clear - GLP-1 medications are not a quick fix and we are seeing a rise in abuse of the medications for a short term fix